The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer ...

NHS England » NHS England appoints two new cancer drugs expert to help patients benefit from a “treatment revolution” ...

LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) ha ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

Ahead of the 10-year anniversary of Tagrisso’s initial FDA approval this fall, AstraZeneca has debuted the first ...

LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for ...

The FDA granted fast track status to DB-1310, a HER3-targeting antibody-drug conjugate, for advanced nonsquamous non-small cell lung cancer.

Panelists discuss how BTK inhibitors represent a promising new oral therapy class that could address both inflammatory and ...

Experts see tolebrutinib as part of a broader shift toward treatments that target the neurodegeneration in MS, not just its ...